(Q34030905)

30 July 2017

1 reference

title

Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy (English)

1 reference

30 July 2017

1 reference

coronary artery disease

1 reference

Isles CG

1 reference

30 July 2017

Paterson JR

series ordinal

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

QJM: An International Journal of Medicine

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

567-574

1 reference

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Dietary reduction of serum cholesterol concentration: time to think again

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2F93.9.567

21 January 2018

Identifiers

DOI

10.1093/QJMED/93.9.567

1 reference

30 July 2017

1 reference